Project Grant R03CA276790

Award Date 9/19/23
Completion Date 8/31/25
Dollars Obligated $168K
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is funding a $602,361 research project at Yale University to develop deep learning-based models for personalized treatment planning of PSMA radiopharmaceutical therapy (RPT) in prostate cancer. The project aims to leverage imaging data from PSMA-PET and SPECT scans to build predictive models that can optimize dosimetry and personalize the dose administered during each cycle of 177Lu-PSMA...
This $435,827 Project Grant from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program supports research conducted by New York University (NYU) School of Medicine to develop deep learning methods for analyzing mass spectrometry imaging (MSI) data. The goal is to make MSI data more accessible to existing machine learning workflows by expanding the dimensionality of the data structure to treat each metabolite or lipid as an individual "color...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $140,511 to Emory University to develop a computational framework that leverages artificial intelligence (AI) visual explanation to guide AI reasoning and communication with medical practitioners for early abdominal cancer diagnosis. The key products and services to be delivered through this 4-year project include: Improving AI sample efficiency by using...
The National Cancer Institute (NCI) awarded a $164,639 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Brown University. The research project aims to employ quantitative image analysis based on deep learning to improve treatment efficacy in image-guided renal tumor ablation. Specifically, the project seeks to develop a novel fully automated pipeline for kidney segmentation and registration using deep learning techniques. This is expected to reduce the...
This $266,614 federal Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund the development of a principled framework to systematically explain AI-based histopathological models for cancer diagnosis and subtyping. The project aims to achieve four key tasks: Develop a "generative explainer" framework to explain DL histopathological models by generating a spectrum of images that can lead to different model predictions....
The National Cancer Institute (NCI) awarded a $762,258 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Cedars-Sinai Medical Center. The project aims to develop and test a natural language processing (NLP) and artificial intelligence (AI) system that provides real-time feedback to patients and physicians on key risks and rewards discussed during prostate cancer treatment consultations. The goal is to improve patient decision-making and physician risk...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) totaling $692,248 will support the development of novel analytic methods and computational tools for diagnosing and characterizing aggressive forms of cancer, particularly prostate cancer. The key objectives are to establish an analytic framework and methodology for "disease ruling" - accurately ruling out or ruling in the presence of aggressive cancer - through the use...
This Project Grant award of $700,611 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will fund a practical randomized controlled trial (RCT) to evaluate the use of artificial intelligence (AI) as a second opinion for the clinical diagnosis of melanoma. The goal is to determine the potential benefits and barriers to AI technology adoption, as well as the impact on reducing the number needed to biopsy (NNB) and maintaining melanoma...
The National Cancer Institute (NCI) awarded a $505,613 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Fred Hutchinson Cancer Center in Seattle, WA. The grant, awarded on December 4, 2024, supports the development of statistical and computational approaches to leverage genomic data and spatial omics technology for precision cancer prevention. The key objectives are to: 1) Create deep learning-based methods to identify tumor subtypes associated with poor outcomes...
This Project Grant award, valued at $245,087.00, was provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The goal of the project is to develop advanced AI systems that can accurately interpret prostate MRI scans by integrating radiologist expertise expressed through standardized PIRADS reporting. The University of Delaware, the prime recipient, will collaborate with Memorial Sloan Kettering radiologists to curate a...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Yale University totals $167,500 and will be executed from September 2023 through August 2025. The primary objectives are to:

  1. Develop deep neural network-based emulation analysis methods and software to objectively quantify the relative effectiveness of drugs, devices, and treatment procedures on cancer prognosis, especially when randomized clinical trials are not feasible. The methodological advancements will expand the scope of emulation analysis, deep learning, causal inference, and observational data analysis.

  2. Conduct emulated clinical trials to analyze the comparative effectiveness of (A) lobectomy versus limited resection for lung cancer survival in the SEER-Medicare elderly population, and (B) radical prostatectomy versus observation for localized prostate cancer survival in the VA population. The findings from these analyses will directly inform clinical practice.

The project will leverage large observational datasets from electronic medical records and insurance claims to complement randomized trials, and deliver user-friendly software tools to enable broader adoption of these advanced analytical techniques. This work has the potential to lead to more definitive findings on cancer treatment effectiveness.

Generated 7/16/24, 1:49 AM